FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308546267> ?p ?o ?g. }

• W4308546267 abstract "<h3>Background</h3> BEMPEG is a pegylated interleukin-2 (IL-2) cytokine prodrug engineered to deliver a controlled and sustained IL-2 pathway stimulation, with the goal of preferentially expanding CD8+ T and natural killer (NK) cells over immunosuppressive regulatory T cells (Tregs) in the tumor microenvironment. In the phase 3 PIVOT IO-001 clinical trial (NCT03635983), BEMPEG+NIVO demonstrated no added clinical benefit over NIVO. This first disclosure of comprehensive biomarker analysis from a randomized controlled trial comparing a next-generation IL-2 agonist+NIVO with NIVO aims to gain mechanistic insights underlying the efficacy results. <h3>Methods</h3> Patients with previously untreated, unresectable, or metastatic melanoma were randomized 1:1 to receive BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W or NIVO 360 mg IV Q3W. Longitudinal changes within Cycle 1 (C1) and 5 (C5) in CD4+ and CD8+ T, NK, and Treg (CD4+CD25+FOXP3+) cell counts, and proliferating (Ki67+) populations, were characterized in blood by flow cytometry. Changes in systemic cytokines, including interferon gamma (IFNγ), were also evaluated. Changes in% tumor cell PD-L1 expression,% CD8+ tumor-infiltrating lymphocytes (TILs), and% FOXP3+ cells from baseline to C1 Day 21 (C1D21) were assessed in tumor biopsies by immunohistochemistry. <h3>Results</h3> In peripheral blood, BEMPEG+NIVO mediated statistically significant increases in CD8+ and CD4+ T, NK, and Treg cell counts, as well as IFNγ levels, from baseline to day 8 of C1 and C5, with limited changes observed with NIVO. Compared with NIVO, BEMPEG+NIVO led to significant increases in proliferating Tregs and NK cells from baseline to D8 of C1 and C5. While significant increases in proliferating CD8+ and CD4+ T cells were observed in C1 and C5 following BEMPEG+NIVO, these effects were attenuated in C5. Systemic IFNγ increases, although significant, were attenuated in C5 with BEMPEG+NIVO. Changes in biomarkers measured in the tumor, including increases in CD8+ TILs, from baseline to C1D21 were similar between treatment arms. <h3>Conclusions</h3> Observations in peripheral blood demonstrated that, in comparison with limited changes with NIVO, BEMPEG+NIVO increased all immune cell subsets interrogated. Despite greater expansion of peripheral CD8+ T cells within C1 following BEMPEG+NIVO vs NIVO, there was no substantive difference in CD8+ TIL increase between the two arms, suggesting no synergistic/additive tumor activity for BEMPEG+NIVO over NIVO. These observations, together with attenuation of peripheral T-cell proliferation over time, potentially explain the lack of added clinical benefit for BEMPEG+NIVO vs NIVO in PIVOT IO-001. Results from this study should be taken into consideration and interrogated further as next-generation IL-2 agonists are developed. <h3>Acknowledgements</h3> The authors would like to thank the patients who participated in this trial and their families; the investigators, study coordinators, and study teams; and Lisa Panting and Yongliang Sun for their flow cytometry work. Editorial support was provided by Emily Motola, PharmD, of Spark Medica Inc. <h3>Trial Registration</h3> NCT03635983 <h3>Ethics Approval</h3> The trial protocols were approved by site institutional review boards or independent ethics committees and conducted according to Good Clinical Practice guidelines, per the International Conference on Harmonisation. Patients provided written informed consent based on Declaration of Helsinki principles. <h3>Consent</h3> Not applicable – no patient-identifiable data reported in this abstract" @default.
• W4308546267 created "2022-11-12" @default.
• W4308546267 creator A5015505110 @default.
• W4308546267 creator A5020414234 @default.
• W4308546267 creator A5025478490 @default.
• W4308546267 creator A5029588412 @default.
• W4308546267 creator A5030834372 @default.
• W4308546267 creator A5037359057 @default.
• W4308546267 creator A5045462330 @default.
• W4308546267 creator A5056741920 @default.
• W4308546267 creator A5058902095 @default.
• W4308546267 creator A5058998750 @default.
• W4308546267 creator A5059401838 @default.
• W4308546267 creator A5063056787 @default.
• W4308546267 creator A5064026461 @default.
• W4308546267 creator A5064373607 @default.
• W4308546267 creator A5085339121 @default.
• W4308546267 creator A5086713437 @default.
• W4308546267 creator A5090633646 @default.
• W4308546267 date "2022-11-01" @default.
• W4308546267 modified "2023-10-17" @default.
• W4308546267 title "1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial" @default.
• W4308546267 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1473" @default.
• W4308546267 hasPublicationYear "2022" @default.
• W4308546267 type Work @default.
• W4308546267 citedByCount "0" @default.
• W4308546267 crossrefType "proceedings-article" @default.
• W4308546267 hasAuthorship W4308546267A5015505110 @default.
• W4308546267 hasAuthorship W4308546267A5020414234 @default.
• W4308546267 hasAuthorship W4308546267A5025478490 @default.
• W4308546267 hasAuthorship W4308546267A5029588412 @default.
• W4308546267 hasAuthorship W4308546267A5030834372 @default.
• W4308546267 hasAuthorship W4308546267A5037359057 @default.
• W4308546267 hasAuthorship W4308546267A5045462330 @default.
• W4308546267 hasAuthorship W4308546267A5056741920 @default.
• W4308546267 hasAuthorship W4308546267A5058902095 @default.
• W4308546267 hasAuthorship W4308546267A5058998750 @default.
• W4308546267 hasAuthorship W4308546267A5059401838 @default.
• W4308546267 hasAuthorship W4308546267A5063056787 @default.
• W4308546267 hasAuthorship W4308546267A5064026461 @default.
• W4308546267 hasAuthorship W4308546267A5064373607 @default.
• W4308546267 hasAuthorship W4308546267A5085339121 @default.
• W4308546267 hasAuthorship W4308546267A5086713437 @default.
• W4308546267 hasAuthorship W4308546267A5090633646 @default.
• W4308546267 hasBestOaLocation W43085462671 @default.
• W4308546267 hasConcept C121608353 @default.
• W4308546267 hasConcept C126322002 @default.
• W4308546267 hasConcept C143998085 @default.
• W4308546267 hasConcept C167672396 @default.
• W4308546267 hasConcept C203014093 @default.
• W4308546267 hasConcept C2776090121 @default.
• W4308546267 hasConcept C2777658100 @default.
• W4308546267 hasConcept C2777701055 @default.
• W4308546267 hasConcept C2779727006 @default.
• W4308546267 hasConcept C2780030458 @default.
• W4308546267 hasConcept C502942594 @default.
• W4308546267 hasConcept C71924100 @default.
• W4308546267 hasConcept C79484868 @default.
• W4308546267 hasConcept C8891405 @default.
• W4308546267 hasConceptScore W4308546267C121608353 @default.
• W4308546267 hasConceptScore W4308546267C126322002 @default.
• W4308546267 hasConceptScore W4308546267C143998085 @default.
• W4308546267 hasConceptScore W4308546267C167672396 @default.
• W4308546267 hasConceptScore W4308546267C203014093 @default.
• W4308546267 hasConceptScore W4308546267C2776090121 @default.
• W4308546267 hasConceptScore W4308546267C2777658100 @default.
• W4308546267 hasConceptScore W4308546267C2777701055 @default.
• W4308546267 hasConceptScore W4308546267C2779727006 @default.
• W4308546267 hasConceptScore W4308546267C2780030458 @default.
• W4308546267 hasConceptScore W4308546267C502942594 @default.
• W4308546267 hasConceptScore W4308546267C71924100 @default.
• W4308546267 hasConceptScore W4308546267C79484868 @default.
• W4308546267 hasConceptScore W4308546267C8891405 @default.
• W4308546267 hasLocation W43085462671 @default.
• W4308546267 hasOpenAccess W4308546267 @default.
• W4308546267 hasPrimaryLocation W43085462671 @default.
• W4308546267 hasRelatedWork W1490834847 @default.
• W4308546267 hasRelatedWork W1531474080 @default.
• W4308546267 hasRelatedWork W1557803273 @default.
• W4308546267 hasRelatedWork W2138864047 @default.
• W4308546267 hasRelatedWork W2384344522 @default.
• W4308546267 hasRelatedWork W2767749856 @default.
• W4308546267 hasRelatedWork W2995822774 @default.
• W4308546267 hasRelatedWork W3161961149 @default.
• W4308546267 hasRelatedWork W3214820661 @default.
• W4308546267 hasRelatedWork W4366173980 @default.
• W4308546267 isParatext "false" @default.
• W4308546267 isRetracted "false" @default.
• W4308546267 workType "article" @default.